Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

IMPORTANCE: Chiral switching, a strategy in which drug manufacturers develop a single-enantiomer formulation of a drug to be substituted for a racemic formulation, allows manufacturers to maintain market exclusivity for drugs losing patent protection, even without demonstrating superior efficacy or...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Aaron S., Zhang, Audrey D., Meyer, Caitlin E., Egilman, Alexander C., Ross, Joseph S., Wallach, Joshua D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103227/
https://www.ncbi.nlm.nih.gov/pubmed/33956134
http://dx.doi.org/10.1001/jamanetworkopen.2021.5731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103227/
https://www.ncbi.nlm.nih.gov/pubmed/33956134
http://dx.doi.org/10.1001/jamanetworkopen.2021.5731

Ejemplares similares